Trial Profile
A retrospective study to identify the prevalence and the susceptibility of Dasatinib-induced Pulmonary Arterial Hypertension in clinical settings and to find marker-based screening strategies for DiPAH
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Aug 2019
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 01 Aug 2019 Results published in the International Journal of Cardiovascular Imaging.
- 13 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association